Spruce Biosciences offers a high-risk, high-reward opportunity as it advances TA-ERT, potentially the first disease-modifying therapy for MPS IIIB, toward FDA approval. TA-ERT demonstrated durable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results